All News

#ACR19 @rheumnow abs1339 Risk of ImmunoRx related toxicity in pts w/pre-existing AI disease+ malignancy &Rx w/ ICIs comparable to pts w/out preexist AI Dx: IrAEs 32%pts w/only 9% severe,grade 3 irAEs, total 41% toxicity of any grade. most common tox dermatitis 18%& colitis 14%

Olga Petryna DrPetryna ( View Tweet)

#acr19 @rheumnow Great debate Who won? Dr Saag (62% yes votes) But Dr Humphrey NO-anabolic stance as first line for GIO make sense for many patients; antiresorptives do work for GIO and cost per fracture prevented is so much less

k dao KDAO2011 ( View Tweet)

#acr19 @rheumnow Great debate Dr Saag rebuttal PRO anabolic 1st line rationale for GIO: - Dr Humphrey herself wrote in 2014 and 2018 that teriparatide can be considered as 1st line for GIO https://t.co/GjMrs0YYdj
k dao KDAO2011 ( View Tweet)
For persistent arthritis after checkpoint inhibitor cessation, DMARDs don’t seem to blunt tumor response. Increasing issue given the number of patients on combo therapy at risk of arthritis persistence post-ICI cessation. Congratulations @cappelliMD &Dr Braaten!! #ACR19 @RheumNow https://t.co/C3N13D3Dqm https://t.co/H66bnMGGkL

Links:

David Liew drdavidliew ( View Tweet)
Which new therapeutic agent in late stage development are you most excited about using in the future? #ACR19 @RheumNow

Philip Robinson philipcrobinson ( View Tweet)

@rheumnow abs1329 Pooled safety data FINCH1-3 Ph3 trials on Filgotinib showed favorable safety profile FIL mono & in combination w/cDMARDs: incidences of MACE 0.2% for FIL, 0.3%adalimumab (ADA), and 0.5% PBO/csDMARD. Incidences of DVT/PE < 0.1% for FIL, 0% ADA& 0.3% PBO/csDMARD https://t.co/NhC6cWplGu
Olga Petryna DrPetryna ( View Tweet)
#acr19 @rheumnow Great debate Rebuttal from Dr Humphrey NO-anabolic 1st line rationale for GIO “While Teri can be considered in certain pts, you should consider bisphos: efficacy and costs —slow and steady win the race”

k dao KDAO2011 ( View Tweet)

Abstr#1808: Those who had been treated with immunosuppressive therapy for their inflammatory arthritis have no apparent impact on tumour response. This has been shown in previous studies. #ACR19 @RheumNow

Maeve Gamble MaeveGamble ( View Tweet)

#ACR19 @rheumnow ABS1590 3 RCTs show blockage of TNFα & IL-12/23 associated w/significant improvement in depressive symptoms in PSA pts. GO-REVEAL depression ⬇️ 31.2 to 19.5% w/golimumab; PSUMIT1 36.2 to 20.3% & PSUMIT2 37.2 to 21.2% ⬇️ w/UST. minimal change w/PBO in all 3 trials

Olga Petryna DrPetryna ( View Tweet)

Why is the placebo response so high in this tildrakizumab study? #ACR19 @RheumNow https://t.co/H8462OP4jI
Philip Robinson philipcrobinson ( View Tweet)
Abstr#1808: Hopkins Arthritis Center. IA due to ICIs. IA persisted by 6 mo (20/41-48.8%). Pts tx with combo cancer tx more likely to have persistent IA. Pts w/ >2 other irAEs had more persistent IA. Pts w/ persisting arthritis tend to have better tumour response. #ACR19 @RheumNow

Maeve Gamble MaeveGamble ( View Tweet)

This clarion work on understanding the spectrum of relapsing polychondritis ⭐️⭐️⭐️⭐️⭐️ Highly Recommend @RheumNow @HealioRheum @HRheuminations @CCalabreseDO @RulaHajjAliMD #ACR19 https://t.co/9YfZ7YyQQh

Links:

Leonard Calabrese LCalabreseDO ( View Tweet)

#acr19 @rheumnow Great debate Dr Humphrey NO-anabolic rationale for GIO: the data! Compared to bisph: -Teri is less effective at higher GC dose - Teri and D-mab don’t protect against wrist GC https://t.co/TrNV3PtS8q
k dao KDAO2011 ( View Tweet)
#ACR19 @rheumnow abs1759 1-y prospective, monocentric, DB, PBO-cont stdy MTX (10mg/wk) vs PBO in erosive hand OA demonstrates no improvement in VAS pain score with MTX. at the same time MTX significantly ⬇️progression of joint damage vs PBO & seems to facilitate bone remodeling

Olga Petryna DrPetryna ( View Tweet)

My hero @philseo who edits @ACRheum ‘s “The Rheumatologist” publication is talking about chondritis, something that also ambushed me #ACR19 @RheumNow https://t.co/LNlFsuHSOc
Philip Robinson philipcrobinson ( View Tweet)
@RheumNow #ACR19 the list is much longer than one would think https://t.co/pRlgMIWmVF

Links:

Olga Petryna DrPetryna ( View Tweet)

Dirk suggesting that at this time, as long as active IBD excluded, relatively reassuring low rates of new onset IBD with IL17a inhibition #ACR19 @rheumnow 4M064 https://t.co/R1eAEObR5P
Dr Irwin Lim _connectedcare ( View Tweet)
If 50% of SpA pts have microscopic bowel disease, 10% have clinically significant bowel disease...should all patients diagnosed with SpA undergo a colonoscopy with biopsies? #ACR19 @RheumNow

Maeve Gamble MaeveGamble ( View Tweet)

Exciting phase 2 data on bimekizumab (dual anti-17A and F) in r-axSpA, looks like 160mg is the go, I hear on the grapevine that they are well into phase 3. Looking forward to the results #ACR19 @RheumNow Abs 3S111 https://t.co/PTCgjWm2EM
Philip Robinson philipcrobinson ( View Tweet)
Previous smoking hx increase risk of UC, but this goes into remission almost immediately when they resume smoking...“The good thing about that is that they stay on their maintenance therapy.” -Dr David Rubin #ACR19 @RheumNow

Maeve Gamble MaeveGamble ( View Tweet)

×